Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

306 questions · 324 findings · 26 reviews

No studies found 59 · 18.2%GRADE not reported 30 · 9.3%Very low 91 · 28.1%Low 62 · 19.1%Moderate 78 · 24.1%High 4 · 1.2%

CLOZAPINE + RISPERIDONE vs CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010)

Quality of life/satisfaction with care for either recipients of care or carers: significant change in quality of life/satisfaction · people with treatment‐resistant schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

ZOTEPINE vs RISPERIDONE

Adverse effects: Extrapyramidal effects ‐ use of antiparkinson medication ‐ vs 4mg risperidone · patients with schizophrenia

It is very uncertain whether ZOTEPINE changes adverse effects: Extrapyramidal effects ‐ use of antiparkinson… compared with RISPERIDONE (very low certainty).

1 finding from 1 review

ZOTEPINE vs RISPERIDONE

Adverse effects: Extrapyramidal effects ‐ use of antiparkinson medication ‐ vs 8mg risperidone · patients with schizophrenia

It is very uncertain whether ZOTEPINE changes adverse effects: Extrapyramidal effects ‐ use of antiparkinson… compared with RISPERIDONE (very low certainty).

1 finding from 1 review

RISPERIDONE vs placebo

Symptoms of delirium within 24 hoursa · terminally ill adults with delirium

Summary of findings: risperidone showed no clear difference in symptoms of delirium within 24 hoursa compared with placebo (low certainty).

1 finding from 1 review

RISPERIDONE vs placebo

Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium

Summary of findings: risperidone showed no clear difference in symptoms of delirium between 24 and 48 hoursa compared with placebo (low certainty).

1 finding from 1 review

RISPERIDONE vs placebo

Adverse events including extrapyramidal effects · terminally ill adults with delirium

Summary of findings: risperidone showed no clear difference in adverse events including extrapyramidal effectsd compared with placebo (low certainty).

1 finding from 1 review

PHASE SPECIFIC TREATMENT (RISPERIDONE + CBT) + SPECIALISED TEAM vs SPECIALISED TEAM

Progression to psychosis ‐ by 12 months · people with psychosis

PHASE SPECIFIC TREATMENT (RISPERIDONE + CBT) + SPECIALISED TEAM probably leads to lower progression to psychosis ‐ by 6 months compared with SPECIALISED TEAM (moderate certainty).

2 findings from 1 review

Group B cognitive behavioural therapy: cognitive behavioural therapy + risperidone vs placebo and cognitive and behavioural therapies

Prodromal symptoms: transition to psychosis Endpoint data (events) · people in the prodromal stage of psychosis

It is very uncertain whether group B cognitive behavioural therapy: cognitive behavioural therapy… changes prodromal symptoms: transition to psychosis Endpoint data (events) compared with cognitive behavioural therapy + placebo (very low certainty).

1 finding from 1 review

Group B cognitive behavioural therapy: cognitive behavioural therapy + risperidone vs placebo and cognitive and behavioural therapies

Adverse effects: specific ‐ doctors' assessment of adverse effects UKU (events) Medium‐term · people in the prodromal stage of psychosis

It is very uncertain whether group B cognitive behavioural therapy: cognitive behavioural therapy… changes adverse effects: specific ‐ doctors' assessment of adverse effects… compared with cognitive behavioural therapy + placebo (very low certainty).

1 finding from 1 review

Group B cognitive behavioural therapy: cognitive behavioural therapy + risperidone vs placebo and cognitive and behavioural therapies

Satisfaction with treatment: leaving the study early Endpoint data (events) · people in the prodromal stage of psychosis

It is very uncertain whether group B cognitive behavioural therapy: cognitive behavioural therapy… changes satisfaction with treatment: leaving the study early Endpoint data… compared with cognitive behavioural therapy + placebo (very low certainty).

1 finding from 1 review

Group C cognitive behavioural therapy: cognitive behavioural therapy + risperidone vs placebo or supportive treatment

Prodromal symptoms: transition to psychosis Endpoint data (events) · people in the prodromal stage of psychosis

It is very uncertain whether group C cognitive behavioural therapy: cognitive behavioural therapy… changes prodromal symptoms: transition to psychosis Endpoint data (events) compared with supportive therapy + placebo (very low certainty).

1 finding from 1 review